Death and dysfunction of these cells, known as retinal ganglion cells, cause vision loss in conditions like glaucoma and MS.
"Our work could lead not only to a better understanding of the biology of the optic nerve, but also to a cell-based human model that could be used to discover drugs that stop or treat blinding conditions," said study leader Donald Zack, from the Johns Hopkins University School of Medicine in US.
The laboratory process entails genetically modifying a line of human embryonic stem cells to become fluorescent upon their differentiation to retinal ganglion cells, and then using that cell line for development of new differentiation methods and characterisation of the resulting cells.
Using a genome editing laboratory tool called CRISPR-Cas9, the researchers inserted a fluorescent protein gene into the stem cells' DNA.
This red fluorescent protein POU4F2 would be expressed only if another gene named BRN3B was also expressed.
Next, they used a technique called fluorescence-activated cell sorting to separate out the newly differentiated retinal ganglion cells from a mixture of different cells into a highly purified cell population.
The cells showed biological and physical properties seen in retinal ganglion cells produced naturally, said Zack.
Researchers also found that adding a naturally occurring plant chemical called forskolin on the first day of the process helped improve the cells' efficiency of becoming retinal ganglion cells.
"It seems we can now isolate the cells and study them in a pure culture, which is something that wasn't possible before," Sluch said.
"We hope that these cells can eventually lead to new treatments for glaucoma and other forms of optic nerve disease," said Zack.
The study was published in the journal Scientific Reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
